DTL
BCRX icon

Dynamic Technology Lab’s BioCryst Pharmaceuticals BCRX Stock Holding History

Dynamic Technology Lab’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,352
Closed -$86K – 925
2024
Q3 		$86K Sell
11,352
-28,807
-72% -$219K 0.01% 945
2024
Q2 		$248K Buy
+40,159
New +$222K 0.03% 735
2023
Q4 		– Sell
-22,609
Closed -$160K – 1044
2023
Q3 		$160K Sell
22,609
-16,216
-42% -$117K 0.02% 819
2023
Q2 		$273K Buy
+38,825
New +$312K 0.03% 739
2022
Q3 		– Sell
-27,257
Closed -$288K – 1132
2022
Q2 		$288K Buy
27,257
+9,240
+51% +$95.3K 0.03% 777
2022
Q1 		$293K Buy
+18,017
New +$289K 0.03% 797
2021
Q4 		– Sell
-26,774
Closed -$385K – 1126
2021
Q3 		$385K Buy
+26,774
New +$422K 0.05% 640
2020
Q3 		– Sell
-20,284
Closed -$97K – 999
2020
Q2 		$97K Sell
20,284
-29,051
-59% -$116K 0.01% 889
2020
Q1 		$99K Buy
+49,335
New +$136K 0.02% 891
2018
Q4 		– Sell
-16,036
Closed -$122K – 982
2018
Q3 		$122K Buy
+16,036
New +$108K 0.02% 938
2017
Q3 		– Sell
-25,885
Closed -$144K – 1037
2017
Q2 		$144K Sell
25,885
-14,305
-36% -$87.1K 0.03% 918
2017
Q1 		$337K Buy
+40,190
New +$280K 0.08% 504
2016
Q2 		– Sell
-19,107
Closed -$54K – 875
2016
Q1 		$54K Buy
+19,107
New +$84.7K 0.01% 868
2015
Q3 		– Sell
-14,397
Closed -$215K – 808
2015
Q2 		$215K Buy
+14,397
New +$164K 0.07% 595
2014
Q1 		– Sell
-15,790
Closed -$120K – 577
2013
Q4 		$120K Buy
15,790
+5,070
+47% +$32.1K 0.08% 455
2013
Q3 		$78K Buy
+10,720
New +$54.4K 0.06% 431

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Dynamic Technology Lab's BCRX Position: Q4 2024 in Review

Dynamic Technology Lab sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2024, closing a stake of 11,352 shares — an estimated $86K sold.

Dynamic Technology Lab first reported a position in BCRX in Q3 2013 and held it in 16 quarters. The position peaked at $385K in Q3 2021. 258 funds tracked by Wall St. Rank hold BCRX as of Q4 2024.

  • Dynamic Technology Lab reported no remaining BioCryst Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Dynamic Technology Lab sold 11,352 BioCryst Pharmaceuticals shares in Q4 2024, an estimated $86K.
  • Dynamic Technology Lab first reported a position in BioCryst Pharmaceuticals in Q3 2013 and held it in 16 quarters.
  • Dynamic Technology Lab's BioCryst Pharmaceuticals position peaked at $385K in Q3 2021.
  • 258 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2024.

Based on Dynamic Technology Lab's 13F filing for Q4 2024, filed 13 Feb 2025.